1. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nature reviews genetics 2004; 5(9): 691-701. [
DOI:10.1038/nrg1427]
2. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127(3): 469-480. [
DOI:10.1016/j.cell.2006.10.018]
3. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nature reviews cancer 2007; 7(2): 79-94. [
DOI:10.1038/nrc2069]
4. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science 1991; 254(5036): 1359-1361. [
DOI:10.1126/science.1962194]
5. Peifer M, Pai LM, Casey M. Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Developmental Biology 1994; 166(2): 543-556. [
DOI:10.1006/dbio.1994.1336]
6. Slusarski DC, Corces VG, Moon RT. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997; 390(6658): 410-413. [
DOI:10.1038/37138]
7. Liu T, DeCostanzo AJ, Liu X, Wang H y, Hallagan S, Moon RT, Malbon CC. G protein signaling from activated rat frizzled-1 to the β-catenin-lef-Tcf pathway. Science 2001; 292(5522):1718-1722. [
DOI:10.1126/science.1060100]
8. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3β associations that regulate β-catenin stabilization are mediated by Gα proteins. Current biology 2005; 15(22):1989-1997. [
DOI:10.1016/j.cub.2005.10.050]
9. Katanaev VL, Ponzielli R, Sémériva M, Tomlinson A. Trimeric G protein-dependent frizzled signaling in Drosophila. Cell 2005; 120(1): 111-122. [
DOI:10.1016/j.cell.2004.11.014]
10. Gao Y, Wang H y. Inositol pentakisphosphate mediates Wnt/β-catenin signaling. The journal of biological chemistry 2007; 282(36): 26490-26502. [
DOI:10.1074/jbc.M702106200]
11. Koval A, Katanaev VL. Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian Frizzled proteins. Biochemical journal 2011; 433(3): 435-440. [
DOI:10.1042/BJ20101878]
12. Najafi SMA. Activators of G proteins inhibit GSK-3β and stabilize β-catenin in Xenopus oocytes. Biochemical and biophysical research communications 2009; 382(2): 365-369. [
DOI:10.1016/j.bbrc.2009.03.027]
13. Salmanian S, Najafi SMA, Rafipour M, Arjomand MR, Shahheydari H, Ansari S, Kashkooli L, Rasouli SJ, Saghaeian Jazi M, Minaei T. Regulation of GSK-3β and β-catenin by Gαq in HEK293T cells. Biochemical and biophysical research communications. 2010; 395(4): 577-582. [
DOI:10.1016/j.bbrc.2010.04.087]
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. The journal of biological chemistry 1951; 193(1): 265-275. [
DOI:10.1016/S0021-9258(19)52451-6]
15. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275(5307): 1787-1790. [
DOI:10.1126/science.275.5307.1787]
16. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398(6726): 422-426. [
DOI:10.1038/18884]
17. He T C, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281(5382): 1509-1512. [
DOI:10.1126/science.281.5382.1509]
18. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF‐20 and DKK1 are transcriptional targets of β‐catenin and FGF‐20 is implicated in cancer and development. The EMBO journal 2005; 24(1): 73-84. [
DOI:10.1038/sj.emboj.7600460]
19. Gilchrist A, Bünemann M, Li A, Hosey MM, Hamm HE. A dominant-negative strategy for studying roles of G proteins in vivo. The journal of biological chemistry 1999; 274(10): 6610-6616. [
DOI:10.1074/jbc.274.10.6610]
20. Gilchrist A, Vanhauwe JF, Li A, Thomas TO, Voyno Yasenetskaya T, Hamm HE. Gα minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation. The journal of biological chemistry 2001; 276(28): 25672-25679. [
DOI:10.1074/jbc.M100914200]
21. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacological reviews 2001; 53(2): 245-282.
22. Haraguchi K, Rodbell M. Carbachol-activated muscarinic (M1 and M3) receptors transfected into Chinese hamster ovary cells inhibit trafficking of endosomes. Proceedings of the national academy of sciences of the United States of America 1991; 88(14): 5964-5968. [
DOI:10.1073/pnas.88.14.5964]
23. Grishina Z, Ostrowska E, Halangk W, Sahin Tóth M, Reiser G. Activity of recombinant trypsin isoforms on human proteinase‐activated receptors (PAR): mesotrypsin cannot activate epithelial PAR‐1,‐2, but weakly activates brain PAR‐1. The British journal of pharmacology 2005; 146(7): 990-999. [
DOI:10.1038/sj.bjp.0706410]
24. Hussmann GP, Yasuda RP, Xiao Y, Wolfe BB, Kellar KJ. Endogenously expressed muscarinic receptors in HEK293 cells augment up-regulation of stably expressed α4β2 nicotinic receptors. The Journal of biological chemistry 2011; 286(46): 39726-39737. [
DOI:10.1074/jbc.M111.289546]
25. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. The American journal of pathology 2003; 162(5): 1503-1513. [
DOI:10.1016/S0002-9440(10)64283-6]
26. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149(6): 1192-1205. [
DOI:10.1016/j.cell.2012.05.012]
27. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 2017; 169(6): 985-999. [
DOI:10.1016/j.cell.2017.05.016]
28. Najafi SMA. Canonical wnt signaling (Wnt/β-Catenin Pathway): A potential target for cancer prevention and therapy. Iranian biomedical journal 2020; 24(5): 264-275. [
DOI:10.29252/ibj.24.5.264]
29. Shevtsov SP, Haq S, Force T. Activation of β-catenin signaling pathways by classical G-protein-coupled receptors: mechanisms and consequences in cycling and non-cycling cells. Cell cycle 2006; 5(20): 2295-2300. [
DOI:10.4161/cc.5.20.3357]
30. Bar Shavit R, Maoz M, Kancharla A, Nag JK, Agranovich D, Grisaru-Granovsky S, Uziely B. G protein-coupled receptors in cancer. International journal of molecular sciences 2016; 17(8): 1320. [
DOI:10.3390/ijms17081320]
31. Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, Yokouchi H, Zhang L, Corriden R, Liu D, Feigen ME, French RP, Lowy AM, Murray F. GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Frontiers in pharmacolog 2018; 9: 431. [
DOI:10.3389/fphar.2018.00431]
32. Lappano R, Maggiolini M. GPCRs and cancer. Acta pharmacologica sinica 2012; 33(3): 351-362. [
DOI:10.1038/aps.2011.183]
33. O'hayre M, Vázquez Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. The emerging mutational landscape of G- proteins and G-protein-coupled receptors in cancer. Nature reviews cancer 2013; 13(6): 412-424. [
DOI:10.1038/nrc3521]